Portola Pharmaceuticals Inc. presented data from its pivotal Phase 3 APEX study for the investigational drug betrixaban at a poster session at the American College of Cardiology’s (ACC) 66th Annual Scientific Session & Expo.
Betrixaban is an oral, once-daily Factor Xa inhibitor anticoagulant that seeks to extend prophylaxis of venous thromboembolism (VTE) in acute medically ill patients with risk factors for VTE. It is being fast-tracked by the U.S. Food and Drug Administration.
The company also presented information on the investigational agent AndexXa (andexanet alfa) at an oral session titled, “Challenging the Standard of Care: Emerging Concepts in VTE Treatment and Prevention.”
AndexXa, an FDA-designated Breakthrough Therapy, is being developed for patients treated with a direct (apixaban, rivaroxaban or edoxaban) or indirect (enoxaparin) Factor Xa inhibitor. Specifically, the drug will be used when life-threatening or uncontrolled bleeding creates a need for the reversal of anticoagulation.
The ACC event was held at the Walter E. Washington Convention Center in Washington, D.C.